DOE Isotope Program working to mitigate isotope supply disruption
With current world events in play, the U.S. Department of Energy Isotope Program has been carefully monitoring global radio- and stable isotope supply chains and have put mitigation plans in place.
If you are having trouble obtaining isotopes, including Ac-225, Am-241, Ba-133, C-14, Cd-109, Ce-139, Cf-252, Co-57, Cs-131, Cs-137, Fe-55, Fe-59, Ge-68, Gd-153, He-3, Ir-192, Kr-85, Mn-54, Ni-63, P-33, Pd-103, Pm-147, Ru-106, Se-75, Sr-82, Sr-90, U-234, W-188, Y-88, enriched stable isotopes, or any other isotope, please contact the National Isotope Development Center at contact@isotopes.gov to convey your concerns and also find out about supply opportunities.
DOE Announces $1 Million for Research on Studies to Accelerate the Evaluation of Novel, Medical Isotopes for Use in Preclinical and Clinical Medical Trials
Earlier this year, the U.S. Department of Energy (DOE) announced $1 million in funding for three awards to advance research and development (R&D) to translate newly developed radioisotopes into evaluation for potential use in preclinical and clinical trials. This funding is part of a key federal program that produces critical isotopes otherwise unavailable or in short supply for U.S. science, medicine, and industry. While this program is administered by the DOE, assessment of submitted proposals was done in coordination with the National Institutes of Health.
Cancer Countermeasures on a Column
 Researchers supported by the DOE Isotope Program are studying the isotope astatine-211 (At-211) for a new cancer treatment called targeted alpha therapy. This type of treatment may do more damage to cancer cells and cause less harm to the rest of the body than current cancer therapies because it emits alpha particles.
|
